Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDF NASDAQ:RZLT NASDAQ:TERN NASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDFCardiff Oncology$1.96+0.5%$3.05$1.90▼$5.64$139.70M1.281.12 million shs1.14 million shsRZLTRezolute$7.24+1.0%$5.90$2.21▼$7.46$623.76M0.03702,427 shs861,477 shsTERNTerns Pharmaceuticals$7.44-1.6%$5.78$1.87▼$11.40$609.08M-0.041.09 million shs1.04 million shsXNCRXencor$8.33-2.6%$8.28$6.92▼$27.24$579.86M0.82713,771 shs830,110 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDFCardiff Oncology-7.14%-11.76%-26.14%-46.13%-15.58%RZLTRezolute+0.70%-0.42%+22.15%+68.71%+50.63%TERNTerns Pharmaceuticals+8.62%+4.28%+38.21%+115.38%-0.79%XNCRXencor+5.17%+8.23%+7.14%-6.04%-51.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDFCardiff Oncology2.7706 of 5 stars3.43.00.00.02.71.70.6RZLTRezolute3.1575 of 5 stars3.62.00.00.03.44.20.0TERNTerns Pharmaceuticals3.9392 of 5 stars3.31.00.04.13.13.30.0XNCRXencor3.833 of 5 stars3.30.00.03.93.50.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDFCardiff Oncology 2.83Moderate Buy$10.10415.31% UpsideRZLTRezolute 3.17Buy$12.5072.65% UpsideTERNTerns Pharmaceuticals 2.60Moderate Buy$15.63110.01% UpsideXNCRXencor 2.67Moderate Buy$22.25167.11% UpsideCurrent Analyst Ratings BreakdownLatest CRDF, RZLT, TERN, and XNCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.009/3/2025XNCRXencorBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$23.00 ➝ $12.009/2/2025XNCRXencorWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$26.008/21/2025XNCRXencorRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$32.00 ➝ $15.008/7/2025XNCRXencorWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$33.00 ➝ $27.008/7/2025XNCRXencorWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$31.00 ➝ $26.008/6/2025CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $10.007/8/2025CRDFCardiff OncologyLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.006/24/2025CRDFCardiff OncologyJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$3.506/18/2025CRDFCardiff OncologyWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDFCardiff Oncology$680K191.76N/AN/A$0.88 per share2.23RZLTRezoluteN/AN/AN/AN/A$2.19 per shareN/ATERNTerns PharmaceuticalsN/AN/AN/AN/A$3.49 per shareN/AXNCRXencor$110.49M5.38N/AN/A$8.70 per share0.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDFCardiff Oncology-$45.43M-$0.87N/AN/AN/A-9,344.14%-77.94%-63.65%11/6/2025 (Estimated)RZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%9/18/2025 (Estimated)TERNTerns Pharmaceuticals-$88.85M-$1.04N/AN/AN/AN/A-27.35%-26.18%11/11/2025 (Estimated)XNCRXencor-$232.62M-$2.40N/AN/AN/A-121.52%-25.75%-18.19%11/5/2025 (Estimated)Latest CRDF, RZLT, TERN, and XNCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/18/2025Q4 2025RZLTRezolute-$0.22N/AN/AN/AN/AN/A8/6/2025Q2 2025XNCRXencor-$0.78-$0.41+$0.37-$0.41$22.59 million$43.61 million8/5/2025Q2 2025TERNTerns Pharmaceuticals-$0.28-$0.26+$0.02-$0.26N/AN/A7/29/2025Q2 2025CRDFCardiff Oncology-$0.19-$0.21-$0.02-$0.21$0.11 million$0.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDFCardiff OncologyN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDFCardiff OncologyN/A4.424.42RZLTRezoluteN/A8.438.43TERNTerns PharmaceuticalsN/A24.7024.70XNCRXencorN/A5.345.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDFCardiff Oncology16.29%RZLTRezolute82.97%TERNTerns Pharmaceuticals98.26%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipCRDFCardiff Oncology7.70%RZLTRezolute18.39%TERNTerns Pharmaceuticals1.50%XNCRXencor5.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDFCardiff Oncology2066.53 million61.40 millionOptionableRZLTRezolute4087.00 million71.00 millionOptionableTERNTerns Pharmaceuticals4087.51 million86.20 millionNot OptionableXNCRXencor28071.32 million67.59 millionOptionableCRDF, RZLT, TERN, and XNCR HeadlinesRecent News About These CompaniesBraidwell LP Boosts Stock Position in Xencor, Inc. $XNCRSeptember 3 at 7:42 AM | marketbeat.comNantahala Capital Management LLC Purchases New Shares in Xencor, Inc. $XNCRSeptember 3 at 7:07 AM | marketbeat.comRafferty Asset Management LLC Purchases 34,765 Shares of Xencor, Inc. $XNCRSeptember 3 at 4:29 AM | marketbeat.comJump Financial LLC Invests $537,000 in Xencor, Inc. $XNCRSeptember 2 at 4:25 AM | marketbeat.comXencor, Inc. $XNCR Shares Sold by Russell Investments Group Ltd.September 2 at 3:49 AM | marketbeat.com161,149 Shares in Xencor, Inc. $XNCR Bought by Nuveen LLCSeptember 1 at 3:32 AM | marketbeat.comPrice T Rowe Associates Inc. MD Decreases Position in Xencor, Inc. $XNCRAugust 30, 2025 | marketbeat.comInvesco Ltd. Raises Holdings in Xencor, Inc. $XNCRAugust 29, 2025 | marketbeat.comXencor to Participate at Upcoming Investor ConferencesAugust 27, 2025 | businesswire.comVanguard Group Inc. Trims Stake in Xencor, Inc. $XNCRAugust 26, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Receives $23.71 Consensus Target Price from BrokeragesAugust 25, 2025 | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Moderate Buy" by AnalystsAugust 24, 2025 | marketbeat.comAberdeen Group plc Grows Holdings in Xencor, Inc. $XNCRAugust 23, 2025 | marketbeat.comXencor, Inc. $XNCR Stock Holdings Lifted by Public Sector Pension Investment BoardAugust 22, 2025 | marketbeat.comXencor price target lowered to $15 from $32 at RBC CapitalAugust 21, 2025 | msn.comQ3 Earnings Estimate for Xencor Issued By Leerink PartnrsAugust 11, 2025 | marketbeat.comWedbush Estimates Xencor's Q3 Earnings (NASDAQ:XNCR)August 11, 2025 | marketbeat.comWilliam Blair Analysts Boost Earnings Estimates for XencorAugust 11, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.37 EPSAugust 10, 2025 | marketbeat.comXencor (XNCR) Receives a Buy from Leerink PartnersAugust 9, 2025 | theglobeandmail.comXencor, Inc. (NASDAQ:XNCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesAugust 9, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesHow Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go?By Jordan Chussler | August 14, 2025Tesla Is Balanced on a Knife Edge: Time to Tread CarefullyBy Sam Quirke | August 8, 2025Amazon’s Chart Just Flashed a Pennant Pattern—Here’s What to DoBy Sam Quirke | August 27, 2025Chevron Stock Outlook: Dividend Growth Meets InflationBy Chris Markoch | August 28, 2025How a Superstore Strategy Fueled MINISO’s 20% Stock SurgeBy Jeffrey Neal Johnson | August 26, 2025CRDF, RZLT, TERN, and XNCR Company DescriptionsCardiff Oncology NASDAQ:CRDF$1.96 +0.01 (+0.51%) Closing price 04:00 PM EasternExtended Trading$1.97 +0.01 (+0.51%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Rezolute NASDAQ:RZLT$7.24 +0.07 (+0.98%) Closing price 04:00 PM EasternExtended Trading$7.23 -0.01 (-0.14%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Terns Pharmaceuticals NASDAQ:TERN$7.44 -0.12 (-1.59%) Closing price 04:00 PM EasternExtended Trading$7.45 +0.01 (+0.08%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.Xencor NASDAQ:XNCR$8.33 -0.22 (-2.57%) Closing price 04:00 PM EasternExtended Trading$8.38 +0.05 (+0.66%) As of 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
